山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (7): 20-25.doi: 10.6040/j.issn.1671-7554.0.2022.0407
彭超,周应芳
PENG Chao, ZHOU Yingfang
摘要： 缓解疼痛,减少出血和促进生育是子宫腺肌病的主要治疗目标。腺肌病药物治疗选择与子宫内膜异位症类似,有非甾体类抗炎药、促性腺激素释放激素类似物(GnRH-a)、复方口服避孕药、孕激素类药物以及中医中药等五大类。子宫腺肌病是一种慢性疾病,需要长期管理。
中图分类号:
| [1] 中国医师协会妇产科医师分会子宫内膜异位症专业委员会. 子宫腺肌病诊治中国专家共识[J]. 中华妇产科杂志, 2020, 55(6): 376-383. [2] 中国医师协会妇产科医师分会, 中华医学会妇产科学分会子宫内膜异位症协作组. 子宫内膜异位症诊治指南(第三版)[J]. 中华妇产科杂志, 2021, 56(12): 812-824. [3] 郎景和. 子宫腺肌症的迷惑与解惑[J]. 中华妇产科杂志, 2020, 55(11): 737-739. [4] 彭超, 周应芳. 子宫内膜异位症的药物治疗[J]. 山东大学学报(医学版), 2019, 57(6): 46-50. PENG Chao, ZHOU Yingfang. Medical treatment of endometriosis: an update [J]. Journal of Shandong University(Health Sciences), 2019, 57(6): 46-50. [5] Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novelinnovations [J]. Lancet, 2021, 397(10276): 839-852. [6] 中华医学会妇产科学分会子宫内膜异位症协作组. 子宫内膜异位症长期管理中国专家共识[J]. 中华妇产科杂志, 2018, 53(12): 836-841. [7] Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis [J]. Fertil Steril, 2018, 109(3): 398-405. [8] 彭超, 周应芳. 子宫腺肌病药物治疗选择及长期管理[J]. 中国实用妇科与产科杂志, 2019, 35(5): 516-519. PENG Chao, ZHOU Yingfang. Drug choice in medical therapy and long-term management for patients with adenomuosis of the uterus [J]. Chinese Journal of Practical Gynecology and Obstetrics, 2019, 35(5): 516-519. [9] No authors listed. ACOG Committee Opinion No. 760 Summary: dysmenorrhea and endometriosis in the adolescent [J]. Obstet Gynecol, 2018, 132(6): 1517-1518. [10] 彭超, 周应芳. 药物治疗在子宫内膜异位症长期管理中的应用和选择[J]. 中国实用妇科与产科杂志, 2021, 37(3): 303-308. PENG Chao, ZHOU Yingfang. Application and selection of medical treatment in the long-term management of endometriosis [J]. Chinese Journal of Practical Gynecology and Obstetrics, 2021, 37(3): 303-308. [11] Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis [J]. Cochrane Database Syst Rev, 2017, 1(1): CD004753. [12] Oladosu FA, Tu FF, Hellman KM. Nonsteroidal anti-inflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment [J]. Am J Obstet Gynecol,2018, 218(4): 390-400. [13] ETIC Endometriosis Treatment Italian Club. When more is not better: 10'don'ts' in endometriosis management. An ETIC* position statement [J]. Hum Reprod Open, 2019, 2019(3): hoz009. [14] 石一复, 张信美, 黄秀峰, 等. 子宫腺肌症[M]. 北京: 人民卫生出版社, 2018: 129-142. [15] Chapron C, Marcellin L, Borghese B, et al. Rethinking mechanisms, diagnosis and management of endometriosis [J]. Nat Rev Endocrinol, 2019, 15(11): 666-682. [16] 彭超, 周应芳. 子宫腺肌病的药物治疗新探索[J]. 中国计划生育和妇产科, 2019, 11(4): 18-20. [17] Matsushima T, Akira S, Fukami T, et al. Efficacy of hormonal therapies for decreasing uterine volume in patients with adenomyosis [J]. Gynecol Minim Invasive Ther, 2018, 7(3): 119-123. [18] 周应芳. 子宫腺肌病药物治疗原则及注意事项[J]. 中国实用妇科与产科杂志, 2017, 34(2): 157-160. ZHOU Yingfang. Principles and precautions of medical treatment for adenomyosis of the uterus [J]. Chinese Journal of Practical Gynecology and Obstetrics, 2017, 34(2): 157-160. [19] Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with Elagolix, an oral GnRH antagonist [J]. N Engl J Med, 2017, 377(1): 28-40. [20] Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of Elagolix in women with endometriosis: results from two extension studies [J]. Obstet Gynecol, 2018, 132(1): 147-160. [21] Barra F, Grandi G, Tantari M, et al. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments [J]. Expert Opin Biol Ther, 2019, 19(4): 343-360. [22] Perricos A, Wenzl R. Efficacy of elagolix in the treatment of endometriosis [J]. Expert Opin Pharmacother, 2017, 18(13): 1391-1397. [23] Vercellini P, Viganò P, Barbara G, et al. Elagolix for endometriosis: all that glitters is not gold [J]. Hum Reprod, 2019, 34(2): 193-199. [24] Barra F, Vitale SG, Seca M, et al. The potential role of elagolix for treating uterine bleeding associated to uterine myomas [J]. Expert Opinion on Pharmacotherapy, 2020, 21(12): 1419-1430. [25] Al-Hendy A, Bradley L, Owens CD, et al. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids [J]. Am J Obstet Gynecol, 2021, 224(1): 72. [26] Muneyyirci-Delale O, Archer DF, Owens CD, et al. Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis [J]. F S Rep, 2021, 2(3): 338-346. [27] Donnez J, Stratopoulou CA, Dolmans MM. Uterine adenomyosis: from disease pathogenesis to a new medical approach using GnRH antagonists [J]. Int J Environ Res Public Health, 2021, 18(19): 9941. [28] Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist(linzagolix): a new therapy for uterine adenomyosis [J]. Fertil Steril, 2020, 114(3): 640-645. [29] Donnez J, Donnez O, Tourniaire J, et al. Uterine adenomyosis treated by Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist: a pilot study with a New ‘Hit Hard First and then Maintain’ regimen of administration [J]. J Clin Med, 2021, 10(24): 5794. [30] 复方口服避孕药临床应用中国专家共识专家组. 复方口服避孕药临床应用中国专家共识[J]. 中华妇产科杂志, 2015, 50(2): 81-91. [31] 周应芳, 彭超, 冷金花. 要重视子宫内膜异位症的一级和二级预防[J]. 中华妇产科杂志, 2020, 55(9): 624-626. [32] Shaaban OM, Ali MK, Sabra AM, et al. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial [J]. Contraception, 2015, 92(4): 301-307. [33] Wu J, Huang Y, Chen L, et al. Treatment of adenomyosis with subcutaneous etonogestrel implants: a clinical observational study in 17 patients [J]. Med Sci Monit, 2018, 24: 6085-6092. doi: 10.12659/MSM.908979. [34] Murji A, Biberoglu K, Leng J, et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary [J]. Curr Med Res Opin, 2020, 36(5): 895-907. [35] Caruso S, Iraci M, Cianci S, et al. Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain [J]. J Pain Res, 2019, 12: 2371-2378. doi:10.2147/JPR.S207599. [36] Lang J, Yu Q, Zhang S, et al. Dienogest for treatment of endometriosis in Chinese women: a placebo-controlled, randomized, double-blind phase 3 study [J]. J Womens Health(Larchmt), 2018, 27(2): 148-155. [37] Osuga Y, Fujimoto-Okabe H, Hagino A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study [J]. Fertil Steril, 2017, 108(4): 673-678. [38] 徐冰, 陈文勤. 子宫内膜异位症治疗药物地诺孕素的研究进展[J]. 中华妇产科杂志, 2016, 51(3): 222-224. [39] 徐冰, 李华军, 贾婉璐, 等. 地诺孕素用于难治性子宫内膜异位症疼痛的临床研究[J]. 中华妇产科杂志, 2021, 56(3): 178-184. [40] Takeuchi A, Koga K, Miyashita M, et al. Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis [J]. Eur J Obstet Gynecol Reprod Biol, 2016, 207: 157-161. doi: 10.1016/j.ejogrb.2016.10.053. [41] Prathoomthong S, Tingthanatikul Y, Lertvikool S, et al. The effects of dienogest on macrophage and natural killer cells in adenomyosis: a randomized controlled study [J]. Int J Fertil Steril, 2018, 11(4): 279-286. [42] Ji M, Yuan M, Jiao X, et al. A cohort study of the efficacy of the dienogest and the gonadotropin-releasinghormone agonist in women with adenomyosis and dysmenorrhea [J]. Gynecol Endocrinol, 2022, 38(2): 164-169. [43] Matsushima T, Akira S, Yoneyama K, et al. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest [J]. Gynecol Endocrinol, 2020, 36(6): 521-524. [44] Neriishi K, Hirata T, Fukuda S, et al. Long-term dienogest administration in patients with symptomatic adenomyosis [J]. J Obstet Gynaecol Res, 2018, 44(8): 1439-1444. [45] Nirgianakis K, Vaineau C, Agliati L, et al. Risk factors for non-response and discontinuation of dienogest in endometriosispatients: a cohort study [J]. Acta Obstet Gynecol Scand, 2021, 100(1): 30-40. [46] Matsubara S, Kawaguchi R, Akinishi M, et al. Subtype I(intrinsic)adenomyosis is an independent risk factor fordienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis [J]. Sci Rep, 2019, 9(1): 17654. [47] Osuga Y, Watanabe M, Hagino A. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis [J]. J Obstet GynaecolRes, 2017, 43(9): 1441-1448. [48] 黄艳, 彭超, 周应芳. 地诺孕素治疗子宫腺肌病的研究进展[J]. 中华妇产科杂志, 2021, 56(12): 876-880. [49] Bahamondes L, Valeria Bahamondes M, Hulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods [J]. Hum Reprod Update, 2015, 21(5): 640-651. [50] 程利南, 狄文, 丁岩, 等. 女性避孕方法临床应用的中国专家共识[J]. 中华妇产科杂志, 2018, 53(7): 1-15. [51] 郎景和, 冷金花, 邓姗, 等. 左炔诺孕酮宫内缓释系统临床应用的中国专家共识[J]. 中华妇产科杂志, 2019, 54(12): 815-825. [52] Benetti-Pinto CL, de Mira TAA, Yela DA, et al. Pharmacological treatment for symptomatic adenomyosis: a systematic review [J]. Rev Bras Ginecol Obstet, 2019, 41(9): 564-574. [53] 李雷, 冷金花, 戴毅, 等. LNG-IUS治疗子宫腺肌病相关重度痛经的前瞻性研究[J]. 中华妇产科杂志, 2016, 51(5): 345-351. [54] 邓婷, 周应芳. 左炔诺孕酮宫内缓释系统下移和脱落的危险因素及防治措施[J]. 中华妇产科杂志, 2019, 54(12): 780-783. [55] 邓婷, 彭超, 黄艳, 等. 影响宫腔镜下放置左炔诺孕酮宫内节育系统脱落的多因素分析[J]. 中国微创外科杂志, 2020, 20(8): 673-677. DENG Ting, PENG Chao, HUANG Yan, et al. Multivariate analysis of influence factors of expulsion of levonorgestrel-releasing intrauterine system inserted by hysteroscopy [J]. Chinese Journal of Minimally Invasive Surgery, 2020, 20(8): 673-677. [56] Che X, Wang J, He J, et al. New application of mifepristone in the treatment of adenomyosis dysmenorrhea [J]. Int J Med Sci, 2020, 17(2): 224-233. [57] 周应芳.子宫肌瘤药物治疗之评价[J]. 实用妇产科杂志, 2016, 32(3): 180-182. [58] Cope AG, Ainsworth AJ, Stewart EA. Current and future medical therapies for adenomyosis [J]. Semin Reprod Med, 2020, 38(2-03): 151-156. [59] Baboo Kalianee Devi, 陈正云, 张信美. 子宫腺肌病患者药物治疗进展[J]. 浙江大学学报(医学版), 2019, 48(2): 142-147. Baboo Kalianee Devi, CHEN Zhengyun, ZHANG Xinmei. Progress on medical treatment in the management of adenomyosis [J]. Journal of Zhejiang University(Medical Sciences), 2019, 48(2): 142-147. [60] 王国云, 王凯, 袁明, 等. 子宫内膜异位症立体化管理体系(山东方案)[J]. 山东大学学报(医学版), 2021, 59(10): 1-16. WANG Guoyun, WANG Kai, YUAN Ming, et al. Multidimensional management system for endometriosis(The Program for Shandong Provence)[J]. Journal of Shandong University(Health Sciences), 2021, 59(10): 1-16. |
| [1] | 王国云,潘臧钰. 子宫腺肌病动物模型研究进展[J]. 山东大学学报 (医学版), 2022, 60(7): 48-55. |
| [2] | 颜磊,陈子江. 子宫腺肌病合并不孕的治疗[J]. 山东大学学报 (医学版), 2022, 60(7): 43-47. |
| [3] | 陶国伟,王芳,董向毅,徐亚瑄,赵琳丽,胡蓓蓓. 子宫腺肌病的超声与MRI诊断及进展[J]. 山东大学学报 (医学版), 2022, 60(7): 56-65. |
| [4] | 艾星子·艾里,郭铮宇,张晓霏. 子宫腺肌病高强度聚焦超声消融治疗研究进展[J]. 山东大学学报 (医学版), 2022, 60(7): 36-42. |
| [5] | 易晓芳,黄季华. 子宫腺肌病的患者教育及全程管理[J]. 山东大学学报 (医学版), 2022, 60(7): 32-35. |
| [6] | 张信美,徐萍. 子宫腺肌病的手术治疗策略[J]. 山东大学学报 (医学版), 2022, 60(7): 26-31. |
| [7] | 冷金花, 史精华. 子宫腺肌病的临床表现[J]. 山东大学学报 (医学版), 2022, 60(7): 1-5. |
| [8] | 郭孙伟,刘惜时. 子宫腺肌病发病机制和病理生理研究进展[J]. 山东大学学报 (医学版), 2022, 60(7): 6-19. |
| [9] | 徐歌,李青,张灿灿,田永杰. 子宫腺肌病组织及原代细胞中PARP-1、HIF-1α的表达及临床意义[J]. 山东大学学报 (医学版), 2022, 60(4): 55-61. |
| [10] | 耿晨,杨阳,赵月,刘浩冉,晁岚. 子宫腺肌病中差异基因筛选及Wilms tumor-1的表达[J]. 山东大学学报 (医学版), 2021, 59(4): 79-86. |
| [11] | 杨贵霞,徐阳,马明明,宋然,朱鹏飞. 宫腹腔镜联合治疗Robert子宫合并子宫腺肌病1例[J]. 山东大学学报 (医学版), 2021, 59(1): 122-124. |
| [12] | 王冰玉,杨阳,晁岚. TOLL样受体4在15例子宫腺肌病中的表达及作用[J]. 山东大学学报 (医学版), 2020, 58(6): 47-52. |
| [13] | 彭超,周应芳. 子宫内膜异位症的药物治疗[J]. 山东大学学报 (医学版), 2019, 57(6): 46-50. |
| [14] | 冷金花,史精华. 子宫内膜异位症长期管理策略[J]. 山东大学学报 (医学版), 2019, 57(6): 1-5. |
| [15] | 林雪艳,李春艳,侯小满,田永杰. PARP-1及EMT标志物在子宫腺肌病在位及异位内膜中的表达[J]. 山东大学学报（医学版）, 2017, 55(9): 36-40. |
|
